Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription

Articles published in PLoS Genet

Retrieve available abstracts of 16 articles:
HTML format

Single Articles

    May 2021
  1. WANG S, Li H, Song M, Tao Z, et al
    Copy number signature analysis tool and its application in prostate cancer reveals distinct mutational processes and clinical outcomes.
    PLoS Genet. 2021;17:e1009557.
    PubMed     Abstract available

    January 2021
  2. WEBER H, Ruoff R, Garabedian MJ
    MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
    PLoS Genet. 2021;17:e1008540.
    PubMed     Abstract available

    December 2020
  3. RAY D, Chatterjee N
    A powerful method for pleiotropic analysis under composite null hypothesis identifies novel shared loci between Type 2 Diabetes and Prostate Cancer.
    PLoS Genet. 2020;16:e1009218.
    PubMed     Abstract available

    March 2020
  4. DAI JY, Wang X, Wang B, Sun W, et al
    DNA methylation and cis-regulation of gene expression by prostate cancer risk SNPs.
    PLoS Genet. 2020;16:e1008667.
    PubMed     Abstract available

    February 2020
  5. YUAN J, Kensler KH, Hu Z, Zhang Y, et al
    Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry.
    PLoS Genet. 2020;16:e1008641.
    PubMed     Abstract available

    October 2019
  6. OLSON A, Le V, Aldahl J, Yu EJ, et al
    The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression.
    PLoS Genet. 2019;15:e1008451.
    PubMed     Abstract available

    January 2019
  7. CANNATARO VL, Townsend JP
    Wagging the long tail of drivers of prostate cancer.
    PLoS Genet. 2019;15:e1007820.

    December 2018
  8. WILK G, Braun R
    regQTLs: Single nucleotide polymorphisms that modulate microRNA regulation of gene expression in tumors.
    PLoS Genet. 2018;14:e1007837.
    PubMed     Abstract available

    November 2018
  9. BROWN AJ, Mao P, Smerdon MJ, Wyrick JJ, et al
    Nucleosome positions establish an extended mutation signature in melanoma.
    PLoS Genet. 2018;14:e1007823.
    PubMed     Abstract available

    August 2018
  10. WANG X, Dong B, Zhang K, Ji Z, et al
    E-cadherin bridges cell polarity and spindle orientation to ensure prostate epithelial integrity and prevent carcinogenesis in vivo.
    PLoS Genet. 2018;14:e1007609.
    PubMed     Abstract available

    May 2018
  11. HAO Y, Bjerke GA, Pietrzak K, Melhuish TA, et al
    TGFbeta signaling limits lineage plasticity in prostate cancer.
    PLoS Genet. 2018;14:e1007409.
    PubMed     Abstract available

    April 2018
  12. PAULO P, Maia S, Pinto C, Pinto P, et al
    Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer.
    PLoS Genet. 2018;14:e1007355.
    PubMed     Abstract available

    September 2017
  13. CAMACHO N, Van Loo P, Edwards S, Kay JD, et al
    Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.
    PLoS Genet. 2017;13:e1007001.
    PubMed     Abstract available

    April 2017
  14. JIN X, Wang J, Gao K, Zhang P, et al
    Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
    PLoS Genet. 2017;13:e1006748.
    PubMed     Abstract available

    March 2017
  15. SURESH S, Durakoglugil D, Zhou X, Zhu B, et al
    SRC-2-mediated coactivation of anti-tumorigenic target genes suppresses MYC-induced liver cancer.
    PLoS Genet. 2017;13:e1006650.
    PubMed     Abstract available

    February 2017
  16. HAGENAARS SP, Hill WD, Harris SE, Ritchie SJ, et al
    Genetic prediction of male pattern baldness.
    PLoS Genet. 2017;13:e1006594.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.